After a very productive day presenting 2 studies at #AACR24 which attracted a lot of interest on the Blueprint Medicines CDK2 inhibitor, we got together with the KeyHunt lab alumni for some Sushi. Linjie Luo Juliana Tuyen Nguyen Kelly K Hunt

Final FY24 funding paylines for competing R01 grants: Non-early stage investigators NCI 10th percentile NIDDK 13th percentile NIA 16th percentile Early stage investigators NCI 17th percentile NIDDK 25th percentile NIA

An amazing scientist, physician and teacher who always sees the glass half full.

A huge congratulations to Kelly. So well deserved. Kelly K Hunt MD Anderson Cancer Center

Remember those days! So care free and magical.

The Keyomarsi lab (Khandan Keyomarsi) and their collaborators found that low molecular weight cyclin E confers a vulnerability to PKMYT1 inhibition in #TNBC. 💡 Learn more in Cancer Research: bit.ly/4elH6gP

Exciting work from our lab reporting that TNBCs that do not respond to chemotherapy have high LMW-E levels that upregulates and stabilizes PKMYT1, leading to enhanced p-CDK1 in TNBCs, which are now more sensitive to the PKMYT1 inhibitor RP-6306. bit.ly/4elH6gP

“The call from Stockholm is mythic in the world of science.” New medicine laureate Gary Ruvkun has received a prank call or two in the past, but today’s was genuine. We talked to him minutes after he heard the news of his #NobelPrize.

Applications for our MD Anderson Cancer Center 2025 CATALYST Summer Training Program are open! This is an excellent opportunity for high school, undergraduate, graduate and medical students to gain exposure to cancer research. More information: bit.ly/3RcwJCH Khandan Keyomarsi Stephanie Watowich

Findings of a study identified biomarkers for predicting treatment response in metastatic breast cancer. The findings suggest that CDK4/6 inhibitors could be enhanced by immune checkpoint inhibitors. Read more: brnw.ch/21wQYKX #EndCancer